Bills › 90th General Assembly
Relating to step therapy protocols and interchangeable biosimilars
Topics:Health care
Where it is now
- Done: IntroducedFebruary 15, 2023
- Done: SubcommitteeFebruary 21, 2023
- Stopped: Senate committeeDied when the General Assembly ended
- Next: Passes the Senate
- Next: House committee
- Next: Passes the House
- Next: To the Governor
- Next: Signed into law
Died when the session ended The 2024 session adjourned on April 19, 2024, the General Assembly’s last regular session. Bills that didn’t pass both chambers died. What’s a funnel?
What’s in it
AI summary Insurance companies and health plans can now require people to try an interchangeable biosimilar before they will pay for a more expensive branded drug. This change affects how insurance coverage works for certain types of prescription medications.1
Read the official explanation
This bill relates to step therapy protocols and interchangeable biosimilars. Under current law, a health carrier, health benefit plan, or utilization review organization may require a covered person (person) to try a prescription drug (drug) with the same generic name and demonstrated bioavailability, or a biological product that is an interchangeable biological product, prior to providing coverage for an equivalent branded drug. The bill allows a health carrier, health benefit plan, or utilization review organization to also require a person to try an interchangeable biosimilar prior to providing coverage for an equivalent branded drug. “Biosimilar” and “interchangeable” are defined in the bill.
Senate subcommittee
Named February 21, 2023. On February 23, 2023 it recommended indefinite postponement. [].
Three legislators hear a bill first and recommend what the committee should do; it’s the best time to weigh in. How to take part